文献速递精神分裂症与精神病性障碍老年精神

严重精神分裂症中的痴呆:认知、临床与遗传特征

Dementia in Severe Schizophrenia.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

这项回顾性队列研究纳入155例严重且极难治疗的精神分裂症(SETRS)住院患者,发现98.7%存在轻度认知障碍、47.1%达到重度痴呆阈值,其认知损害模式不同于阿尔茨海默病和额颞叶痴呆,APOE4频率显著低于AD和路易体痴呆,常见痴呆病因均不能解释。

要点

  • SETRS患者中98.7%MoCA低于26分,47.1%低于10分,平均MoCA 9.8分。
  • SETRS的MoCA条目模式与社区精神分裂症者高度一致(r=0.86),不同于AD和FTD。
  • SETRS中APOE4频率14.4%,显著低于AD(33.6%)和LBD(24.7%)。

核心结论

  • 在155例SETRS患者中,常见的精神分裂症痴呆解释(如共病阿尔茨海默病或心血管危险因素)均不成立。
  • 其认知损害模式不同于AD、FTD和LBD,但重现并加重了社区精神分裂症的认知模式。

研究设计与样本

  • 纳入155例符合DSM-5精神分裂症标准且连续住院≥5年的SETRS患者,排除司法住院、已知医学性精神病病因或近期物质滥用。
  • 认知、临床和遗传数据与NACC数据集中的AD、FTD、LBD、VD患者及健康对照比较。

主要发现

  • 155例SETRS患者平均(SD)年龄59.3(10.3)岁,女性56例(36.1%)。
  • 153/155(98.7%)MoCA低于轻度认知障碍界值26分,73/155(47.1%)低于重度痴呆界值10分,平均(SD)MoCA 9.8(6.4)。
  • SETRS的MoCA条目模式与社区精神分裂症者平行(Pearson r=0.86;P<.001),不同于AD和FTD。
  • 无参与者携带孟德尔痴呆基因致病性变异;SETRS的APOE4等位基因频率14.4%,低于AD的33.6%(OR 0.33;95%CI 0.20-0.53;P<.001)和LBD的24.7%(OR 0.51;95%CI 0.29-0.89;P=.01)。
  • 认知损害不能归因于病前智力障碍、努力不足、药物、心血管代谢危险因素或机构化。

关键数值与推荐

  • MoCA轻度认知障碍界值为26分,重度痴呆界值为10分。
  • SETRS的APOE4频率14.4%,AD为33.6%(OR 0.33;95%CI 0.20-0.53;P<.001),LBD为24.7%(OR 0.51;95%CI 0.29-0.89;P=.01)。

临床怎么用

  • 对长期住院的严重精神分裂症患者应常规评估认知功能,警惕重度痴呆水平损害。
  • 不应默认将精神分裂症患者的痴呆归因于共病阿尔茨海默病或心血管危险因素。
  • APOE4检测在SETRS痴呆评估中的解释需谨慎,其频率显著低于典型痴呆。

局限性

  • 回顾性队列设计,样本来自纽约州立医院连续住院的SETRS患者,外推需谨慎。
  • 原文未报告遗传数据的具体样本量或缺失情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dementia develops in individuals with schizophrenia 4- to 20-fold more frequently than in the general population, but its etiology remains unexplained. OBJECTIVE: To characterize the cognitive, clinical, and genetic features of dementia in individuals with severe, extremely treatment-resistant schizophrenia (SETRS). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study among individuals with SETRS was conducted at New York state hospitals from December 2017 through July 2019. All participants met DSM-5 schizophrenia criteria and were continuously hospitalized for 5 years or more. Exclusion criteria included forensic hospitalization, known medical causes of psychosis, or recent substance abuse. Cognitive, clinical, and genetic data were compared to data from individuals from the National Alzheimer Coordinating Center dataset, including those with Alzheimer disease (AD), frontotemporal dementia (FTD), Lewy body dementia (LBD), or vascular dementia (VD), along with healthy controls. Data were analyzed from January 2025 through December 2025. MAIN OUTCOMES AND MEASURES: Multiple regression was used to analyze the effects of demographic, clinical, and genetic factors on the Montreal Cognitive Assessment (MoCA). RESULTS: In this study's cohort of 155 individuals with SETRS (mean [SD] age, 59.3 [10.3] years; 56 female participants [36.1%]), 153 of 155 (98.7%) scored below the cutoff of 26 for mild cognitive impairment, and 73 of 155 (47.1%) scored below the cutoff of 10 for severe dementia (mean [SD] MoCA score, 9.8 [6.4]). At the item level, the MoCA profile of SETRS differed from those of AD and FTD but paralleled that of community-dwelling individuals with schizophrenia (Pearson r = 0.86; P < .001). No participants carried pathogenic variants in mendelian dementia genes; APOE4 allele frequency was significantly lower in SETRS (14.4%) than in AD (33.6%; odds ratio [OR], 0.33; 95% CI, 0.20-0.53; P < .001) or LBD (24.7%; OR, 0.51; 95% CI, 0.29-0.89; P = .01). Cognitive impairment was not attributable to premorbid intellectual disability, poor effort, medications, cardiometabolic risk factors, or institutionalization. CONCLUSIONS AND RELEVANCE: In this cohort study of 155 individuals with SETRS, none of the commonly proposed explanations for schizophrenia dementia (eg, comorbid Alzheimer disease or cardiovascular risk factors) proved viable. The pattern of cognitive impairments differed from those of Alzheimer disease, frontotemporal dementia, and Lewy body dementia, but recapitulated and intensified that of community-dwelling schizophrenia.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pathak US, Mehralizade A, Goldberg TE, et al. Dementia in Severe Schizophrenia. JAMA Psychiatry. 2026. PMID: 41920573. doi:10.1001/jamapsychiatry.2026.0171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。